The aim of the “European network staff eXchange for integrAting precision health in the health Care sysTems (ExACT)” is to train a new generation of professionals that can contribute to the future of health and healthcare (HC), by providing high-quality, multidisciplinary knowledge in precision health. The greater personalisation of HC is a driver of innovation for research, and for the healthcare system and industry. Still policy makers, HC professionals, citizens, and private companies need to take some steps to realize its potential. In order to harness this challenging landscape, the ExACT consortium provides a cohesive framework for training staff across 7 EU Countries, 1 AC and 2 TCs. During 4 years, the staff involved will be trained on research topics not available at the home institutions thanks to 74 secondments. They will attend courses, workshops, seminars, conferences, and will participate in organizing outreach activities, thus acquiring new skills. Research topics include: Integration of Big Data and digital solutions into the HC systems; Designing and promoting innovative citizen engagement models; Education of healthcare professionals and leadership; Health Technology Assessment in precision health; Ethical-legal, social, organisational and policy issues surrounding precision health. ExACT is embedded in existing cooperation structures, such as the RISE-PRECeDI project, IC PerMed, and CSA TO-REACH. The consortium consists of 14 beneficiaries and 2 partners, of which 10 are academic institutions including Stanford University where a precision health program has been launched, and 7 non academics including 2 SMEs. The participants will produce key reports, policy recommendations, scientific publications, and information materials for citizens, thus fostering public-private interactions. In the long run, ExACT will foster the integration of precision health in the EU HC systems, thus contributing to better health for Europeans citizens.

"PROPHET - a PeRsOnalized Prevention roadmap for the future HEalThcare" will develop a Strategic Research and Innovation Agenda (SRIA) for Personalized Prevention, in order to support the implementation of innovative, sustainable and effective personalized programmes to prevent common chronic diseases. Technological biomedical advances (including omics data and digital tools) make risk stratification at the individual level possible. However, development of Personalized Prevention approaches must be accompanied by healthcare system transition, including citizen engagement, healthcare professional education and addressing organisational, social and legal issues. PROPHET will be centred around stakeholder engagement and the SRIA co-creation process in relation to three main strands of activities: Mapping, Assessment, and Building. Firstly, we will summarize, evaluate and discuss with the relevant stakeholders the extent to which all these new technologies can synergise (Mapping). Secondly, we will design a holistic framework (the PROPHET Framework) that will include all the necessary aspects to appraise Personalized Prevention approaches and their adoption by Public Health Authorities (Assessment). Thirdly, we will support the introduction of Personalised Prevention Programmes by providing guidelines for their design, engaging with healthcare professionals (especially those working with policy makers), and increasing health literacy at the population level on the benefits of Personalized Prevention (Building). PROPHET will liaise with other key current and forthcoming initiatives at EU level, such as ICPerMed, European Partnership (EP) PerMed, the CSA Beyond 1 Million Genomes (B1MG), and the EP on Transforming Health and Care Systems. The consortium consists of 18 beneficiaries and 2 affiliated entities across 12 EU Countries, and a large number of stakeholders already engaged from different Target Groups.

In order to strengthen the sustainability and resilience of health services and systems a unique consortium of governmental and funding organizations plus research institutes, has expressed the ambition to systematically learn from the organisation of care in other settings. Overall objective of TO-REACH is to provide groundwork for a future joint research programme that will contribute to the resilience, effectiveness, equity, accessibility and comprehensiveness of health services and systems. We will do so along two work streams: A) We will develop a research program on cross-border learning from good (or even innovative) models of care and the conditions needed to transfer them to other settings for implementation. It could refer to anywhere in the care chain depending on the priorities as identified in a Strategic Research Agenda (SRA) within this project. Conceptual, methodological and empirical advancement will be achieved through 4 meta-questions that will instruct research under a future joint research programme, linking to what counts as good models of care, what are the conditions required for transferability, what are the conditions for up-scaling, and how do they contribute to the performance of health care organisations and systems. B) We will build a platform for funding organizations that allows for collaboration and coordination in the project and projected joint research programme. This will synchronize priorities and activities, hence improving the quality and applicability of research with a focus on the topic areas as described under A. TO-REACH will pursue five specific objectives: Mapping health system challenges and priorities by synthesizing different materials and stakeholder inputs; Developing a framework and providing a knowledge synthesis on the above-mentioned meta-questions; Establishing sustainable cooperation of research funding bodies and links with other initiatives; Developing a SRA through agenda setting at European and Member State level; Disseminating the results of TO-REACH.

Cardiovascular diseases (CVD) present a significant public health challenge throughout Europe, being the leading cause of morbidity and a major contributor to mortality. Despite technological advancements and preventative strategies, the burden of CVD remains substantial, and the cardiac care pathways across Europe are inadequately mapped. The overarching goal of the EuroHeartPath consortium is to transform cardiovascular care pathways across the continuum of care. By adopting a pan-European scope and facilitating cross-country comparisons, EuroHeartPath aims to elucidate how care is organized and delivered, providing deeper insights and identifying best practices for integration with the support of stakeholders, including ESC, WONCA, EUPHA, and EPA. EuroHeartPath will simultaneously conduct 18 pathfinder studies to optimize the personalized early detection, diagnosis, monitoring, and treatment of heart failure, atrial fibrillation, ventricular fibrillation, and coronary disease, with a particular emphasis on prevention. These studies are categorized into four key areas: 1) novel artificial intelligence (AI) and machine learning applications, such as automated AI analysis of ECGs and Holters, and AI for predicting cardiomyopathies and cardiovascular events; 2) digital health integration, aimed at improving the diagnosis of aortic stenosis and enhancing secondary prevention measures; 3) point-of-care testing, including the use of point-of-care diagnostics in primary practice and ambulances to exclude heart failure; and 4) technology and robotics, encompassing robotic echocardiography and invasive diagnostics in obstructive epicardial coronary artery disease. EuroHeartPath will create a paradigm shift in the management and treatment of heart disease, offering substantial scientific, societal, and economic impacts across the entire patient health journey with a patient centric approach.

The aim of the Personalized pREvention of Chronic DIseases consortium (PRECeDI) is to provide high-quality, multidisciplinary knowledge through training and research in Personalized Medicine (PM), with specific reference to prevention of chronic diseases. There is a large consensus that PM is a driver of innovation for research and health care, and also for the health care system and industry as a whole. In order to harness the potential of this new concept, the PRECeDI consortium provides a cohesive framework for training staff from academic and non-academic (NA) institutions on research topics related to PM, with specific reference to the prevention of chronic diseases where there is a lack of substantial evidence, though the potential is huge. The acquisition of skills from staff will come from dedicated secondments aimed at training on research topics not available at the home institutions, and attendance to courses, workshops, seminars, conferences. The goal of secondment is to enable staff to make informed decisions for appropriately serve health care systems, new biotech industries and policy makers at the dawn of the post-genomic era PRECeDI is a multidisciplinary group of institutions working on different facets of PM, from basic research, to economic evaluations, health service organization, and ethical, social, and policy issues. The consortium is embedded in existing cooperation structures, such as the PerMed project and the Erasmus Mundus ERAWEB II program, with additional leading SMEs in Europe and Canada as beneficiaries. The consortium consists of 8 beneficiaries and 3 partners, of which 7 are academic institutions and 4 NA, including 2 SMEs. During 4-years, 23 ESRs and 7 ERs will be seconded to 11 institutions, where researchers will be supported by a team of leading EU scientists in PM-related disciplines. In the long run, PRECeDI will foster the integration of PM in the field of prevention, thus contributing to better health for Europe’s citizen